Targeted Therapies & Future Directives: RNAi Drug Delivery Market

1
Targeted Therapies Future Directives RNAi Drug
Delivery Market According to Inkwood Research,
the global RNA interference (RNAi) drug delivery
market is expected to grow at a CAGR of 22.24
over the forecast period 20242032. Innovations
in pharmaceuticals have propelled RNA
interference (RNAi) drug delivery to the
forefront of oncology treatment.
RNAi utilizes the bodys molecular mechanisms to
silence disease-causing genes, offering precise
therapeutic interventions with minimal side
effects. This advancement has elevated
significant progress in nanoparticle
technologies, substantially enhancing drug
delivery efficacy. Nanoparticle- based RNAi
therapies allow for targeted delivery to tumor
sites while minimizing systemic side
effects. Leading players like Pfizer (Germany)
are pioneering nanoparticle-based RNAi therapies,
focusing on advanced cancer treatments. These
innovations, in turn, reflect a commitment to
integrating modern research with industrial
expertise, revolutionizing cancer therapy
strategies globally. Request a FREE sample of the
RNAi Drug Delivery Market RNAi Drug Delivery
Market Catalysts for Pharma Innovations RNA
interference (RNAi) was first discovered and
described in 1998 by Andrew Fire and Craig Mello,
leading to their Nobel Prize in Physiology in
2006. Their pioneering research demonstrated that
double-stranded RNA (dsRNA) could silence
specific genes by interfering with genetic
expression. This breakthrough laid the foundation
for RNAi to emerge as a powerful tool in
molecular biology
and potential therapeutic applications.
2

• Initially, RNA therapies focused on rare diseases
  but gained crucial momentum with mRNA
• vaccines during the COVID-19 pandemic, validating
  RNA technologies globally. This success spurred
  substantial investment and broadened development
  efforts into diverse therapeutic areas like
  neurology and metabolic disorders.
• The evolution of RNA-based therapeutics has been
  intricately linked with innovations in drug
  delivery systems. Early on, cationic liposomes
  were employed to form protective complexes with
  mRNA, shielding it from degradation.
• Liposome nanoparticles (LNPs) further emerged as
  sophisticated carriers, featuring lipid bilayer
  shells encapsulating mRNA payloads. LNPs have
  demonstrated safety and efficacy in delivering
  RNA therapeutics, facilitating robust immune
  responses and enabling local or systemic protein
  expression.
• Furthermore, polymers like polyethyleneimine
  (PEI) and poly-amido-amine (PAA) are investigated
  for mRNA delivery, forming nanoparticles to
  improve cellular uptake and intracellular
  delivery efficiency.
• In essence, a meta-analysis of biopharma
  intelligence databases shows substantial trends.
  It includes commercial sales, investments, and
  the scope of preclinical and clinical RNA
  programs over the years.
• Read on to discover the substantial growth in the
  RNA-based pharmaceuticals sphere
• By 2022, the market capitalization of RNA-based
  therapies has surpassed 0.1 trillion, marking it
  as one of the fastest-growing segments in modern
  medicine.
• The RNA-based companies market cap surged from
  3 billion in 2012 to 228 billion in 2021.
• Products like nusinersen, an ASO treatment for
  spinal muscular atrophy, achieved peak sales of
  2.1 billion in 2019.
• Similarly, inclisiran, the first siRNA approved
  for treating dyslipidemia, is projected to reach
  2.7 billion in sales by 2028. (Source)
• As a result, RNA therapies are expanding, pushed
  by technological advancements and increasing
  confidence in their competence across a wide
  range of medical applications.
• Click here to get more insights about the Global
  RNAi Drug Delivery Market
• From Oncogenes to Angiogenesis RNA Interference
  in Cancer Research
• RNA interference (RNAi) technology has
  revolutionized cancer research by offering a
  powerful tool to study and potentially treat
  various types of cancers. It operates through the
  silencing of specific genes implicated in
  tumorigenesis and metastasis.
• One of the earliest applications of RNAi in
  cancer research was the targeting of oncogenes
  like K-Ras, which play critical roles in
  promoting tumor growth. By suppressing the
  expression of oncogenes such as Bcl-2, CDK-2,
  Mdm-2, PKC-a, TGF-ß1, H-Ras, VEGF, and GFP, RNAi
  has shown efficacy in inhibiting cancer cell
  proliferation.
• RNA drug interference has been used to target
  viral oncogenes in virally induced cancers, such
  as cervical cancer (HPV) and hepatocellular
  carcinoma (HBV), offering potential therapeutic
  avenues. Additionally, RNAi studies on tumor
  suppressor genes like Rb have elucidated their
  roles in cancer

progression through pathways like dE2F/dDP/RBF.
3

• This drug interference has also been instrumental
  in studying DNA repair mechanisms by targeting
  genes such as Rad51, which is crucial for
  preventing tumor formation. It has identified
  nucleases involved in chromosomal DNA degradation
  and explored checkpoint responses by targeting
  genes like ATR.
• In the context of cancer invasion and metastasis,
  RNAi-mediated inhibition of genes such
• as RECK and CXCR4 has demonstrated potential in
  regulating tumor cell migration and invasion.
  RNAi has further targeted angiogenesis-related
  proteins like VEGF and HIF, shedding light on
  their roles and potential as therapeutic targets.
  Moreover, RNAi is pivotal in studying
  anti-apoptotic genes
• like livin, Bcl-2, and xIAP, enhancing cancer
  cell sensitivity to traditional treatments.
• In this regard, according to Inkwood Research,
  oncology was the major application in the global
  RNA interference (RNAi) drug delivery market in
  2023.
• Kindly click here to view the LinkedIn post
  related to this market
• Nanoparticle Formulations in RNAi Drug Delivery
  Industry
• Nanoparticle technology serves as versatile drug
  carriers that can be customized to overcome the
  limitations of traditional delivery systems. The
  technology enables precise control over the
  design and construction of drugs, influencing
  their size and shape.
• By conjugating therapeutic agents, nanoscale
  methods create adaptable biocomposites that offer
  advantages in drug delivery and imaging.
  Intracellular targeting further aims to deliver
  drugs to specific sites within cells, such as
  tissues, organelles, or compartments.
• Market Position As per Inkwood Research,
  nanoparticle drug delivery was the largest
  technology in the global RNA interference (RNAi)
  drug delivery market in 2023.
• Moving ahead, solid, lipid and polymer-based
  nanoparticle delivery systems are widely used in
  pharmaceutical and biomedical industries. Leading
  pharmaceutical and biomedical companies
  extensively utilize these drug delivery systems
  to enhance therapeutic potency and targeted drug
  delivery.
• Explore how top pharmaceutical companies utilize
  nanoparticle-based drug delivery to advance
  targeted therapies
• Pfizer Pfizer employs nanoparticle technology in
  products like Abraxane for cancer therapies. It
  enhances chemotherapy delivery directly to tumors
  while reducing systemic side effects.
• Merck Merck utilizes nanoparticles in Gardasil
  for vaccines and gene therapies, improving
  vaccine efficacy and enabling targeted delivery
  of genetic materials.
• Johnson Johnson Johnson Johnson applies
  polymer-based nanoparticles in products like
  Risperdal Consta for diseases like schizophrenia,
  improving drug stability and targeted delivery.
• Novartis Novartis uses lipid-based technologies
  in products like Kisqali for breast cancer
  treatment, improving drug solubility and
  extending circulation times.
• Developments in nanoparticle-based drug delivery
  by these companies lead to advancements in their
  product offerings, driving precision medicine and
  personalized therapies globally. Hence, this
  progress positions them as leaders in
  cutting-edge healthcare solutions.

4

• As advancements in RNAi drug delivery accelerate,
  there is a rising demand for precise and
  effective therapeutic solutions. With increasing
  research and investment in innovative
  technologies, the RNA interference (RNAi) drug
  delivery market is estimated to experience
  developing growth during the forecast period.
• Explore the market insights in this YouTube video
  by clicking here
• Cant find what youre looking for? Talk to an
  expert NOW! FAQs
• Which diseases are targeted by RNAi drug delivery
  therapies?
• A RNAi therapies target a wide range of
  diseases, including genetic disorders, viral
  infections, neurodegenerative diseases, and
  various types of cancer. These therapies aim to
  intervene at the genetic level to treat
  underlying causes of disease.
• What are the current challenges in RNAi drug
  delivery development?
• A The challenges in RNAi drug delivery include
  optimizing the delivery of RNA molecules to
  specific tissues, mitigating immune responses to
  synthetic RNA, and ensuring their safety and
  efficacy in clinical settings. Ongoing research
  focuses on refining delivery systems to
  effectively address these hurdles.